Selected research
Market Outlook & Growth Opportunities
Global IL-12 Antibody Market Outlook and Growth Opportunities 2026
Market perspective
The global IL-12 Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for IL-12 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for IL-12 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for IL-12 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the IL-12 Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the IL-12 Antibody market include Atlas Antibodies, Bio X Cell, BioLegend, FineTest, GeneTex, Miltenyi Biotec, NSJ Bioreagents, ProSci and Proteintech, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global IL-12 Antibody market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of IL-12 Antibody and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents IL-12 Antibody revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global IL-12 Antibody market.
IL-12 Antibody Segment by Company
Atlas Antibodies
Bio X Cell
BioLegend
FineTest
GeneTex
Miltenyi Biotec
NSJ Bioreagents
ProSci
Proteintech
Santa Cruz Biotechnology
United States Biological
Thermo Fisher Scientific
IL-12 Antibody Segment by Type
Monoclonal
Polyclonal
IL-12 Antibody Segment by Application
Western Blot
Flow Cytometry
Immunoprecipitation
Others
IL-12 Antibody Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global IL-12 Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the IL-12 Antibody key companies, revenue, market share, and recent developments.
3. To split the IL-12 Antibody breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions IL-12 Antibody market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify IL-12 Antibody significant trends, drivers, influence factors in global and regions.
6. To analyze IL-12 Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IL-12 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of IL-12 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IL-12 Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global IL-12 Antibody industry.
Chapter 3: Detailed analysis of IL-12 Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of IL-12 Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of IL-12 Antibody in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Monoclonal
- Polyclonal
Applications
- Western Blot
- Flow Cytometry
- Immunoprecipitation
- Others
Companies covered
- Atlas Antibodies
- Bio X Cell
- BioLegend
- FineTest
- GeneTex
- Miltenyi Biotec
- NSJ Bioreagents
- ProSci
- Proteintech
- Santa Cruz Biotechnology
- United States Biological
- Thermo Fisher Scientific
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global IL-12 Antibody Market Size, 2021 VS 2025 VS 2032
- 1.3 Global IL-12 Antibody Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 IL-12 Antibody Market Dynamics
- 2.1 IL-12 Antibody Industry Trends
- 2.2 IL-12 Antibody Industry Drivers
- 2.3 IL-12 Antibody Industry Opportunities and Challenges
- 2.4 IL-12 Antibody Industry Restraints
3 IL-12 Antibody Market by Company
- 3.1 Global IL-12 Antibody Company Revenue Ranking in 2025
- 3.2 Global IL-12 Antibody Revenue by Company (2021-2026)
- 3.3 Global IL-12 Antibody Company Ranking (2024-2026)
- 3.4 Global IL-12 Antibody Company Manufacturing Base and Headquarters
- 3.5 Global IL-12 Antibody Company Product Type and Application
- 3.6 Global IL-12 Antibody Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global IL-12 Antibody Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 IL-12 Antibody Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 IL-12 Antibody Market by Type
- 4.1 IL-12 Antibody Type Introduction
- 4.1.1 Monoclonal
- 4.1.2 Polyclonal
- 4.2 Global IL-12 Antibody Sales Value by Type
- 4.2.1 Global IL-12 Antibody Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global IL-12 Antibody Sales Value by Type (2021-2032)
- 4.2.3 Global IL-12 Antibody Sales Value Share by Type (2021-2032)
5 IL-12 Antibody Market by Application
- 5.1 IL-12 Antibody Application Introduction
- 5.1.1 Western Blot
- 5.1.2 Flow Cytometry
- 5.1.3 Immunoprecipitation
- 5.1.4 Others
- 5.2 Global IL-12 Antibody Sales Value by Application
- 5.2.1 Global IL-12 Antibody Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global IL-12 Antibody Sales Value by Application (2021-2032)
- 5.2.3 Global IL-12 Antibody Sales Value Share by Application (2021-2032)
6 IL-12 Antibody Regional Value Analysis
- 6.1 Global IL-12 Antibody Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global IL-12 Antibody Sales Value by Region (2021-2032)
- 6.2.1 Global IL-12 Antibody Sales Value by Region: 2021-2026
- 6.2.2 Global IL-12 Antibody Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America IL-12 Antibody Sales Value (2021-2032)
- 6.3.2 North America IL-12 Antibody Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe IL-12 Antibody Sales Value (2021-2032)
- 6.4.2 Europe IL-12 Antibody Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific IL-12 Antibody Sales Value (2021-2032)
- 6.5.2 Asia-Pacific IL-12 Antibody Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America IL-12 Antibody Sales Value (2021-2032)
- 6.6.2 South America IL-12 Antibody Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa IL-12 Antibody Sales Value (2021-2032)
- 6.7.2 Middle East & Africa IL-12 Antibody Sales Value Share by Country, 2025 VS 2032
7 IL-12 Antibody Country-level Value Analysis
- 7.1 Global IL-12 Antibody Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global IL-12 Antibody Sales Value by Country (2021-2032)
- 7.2.1 Global IL-12 Antibody Sales Value by Country (2021-2026)
- 7.2.2 Global IL-12 Antibody Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.3.2 USA IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.7.2 France IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.14.2 China IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.17.2 India IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt IL-12 Antibody Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt IL-12 Antibody Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt IL-12 Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Atlas Antibodies
- 8.1.1 Atlas Antibodies Company Information
- 8.1.2 Atlas Antibodies Business Overview
- 8.1.3 Atlas Antibodies IL-12 Antibody Revenue and Gross Margin (2021-2026)
- 8.1.4 Atlas Antibodies IL-12 Antibody Product Portfolio
- 8.1.5 Atlas Antibodies Recent Developments
- 8.2 Bio X Cell
- 8.2.1 Bio X Cell Company Information
- 8.2.2 Bio X Cell Business Overview
- 8.2.3 Bio X Cell IL-12 Antibody Revenue and Gross Margin (2021-2026)
- 8.2.4 Bio X Cell IL-12 Antibody Product Portfolio
- 8.2.5 Bio X Cell Recent Developments
- 8.3 BioLegend
- 8.3.1 BioLegend Company Information
- 8.3.2 BioLegend Business Overview
- 8.3.3 BioLegend IL-12 Antibody Revenue and Gross Margin (2021-2026)
- 8.3.4 BioLegend IL-12 Antibody Product Portfolio
- 8.3.5 BioLegend Recent Developments
- 8.4 FineTest
- 8.4.1 FineTest Company Information
- 8.4.2 FineTest Business Overview
- 8.4.3 FineTest IL-12 Antibody Revenue and Gross Margin (2021-2026)
- 8.4.4 FineTest IL-12 Antibody Product Portfolio
- 8.4.5 FineTest Recent Developments
- 8.5 GeneTex
- 8.5.1 GeneTex Company Information
- 8.5.2 GeneTex Business Overview
- 8.5.3 GeneTex IL-12 Antibody Revenue and Gross Margin (2021-2026)
- 8.5.4 GeneTex IL-12 Antibody Product Portfolio
- 8.5.5 GeneTex Recent Developments
- 8.6 Miltenyi Biotec
- 8.6.1 Miltenyi Biotec Company Information
- 8.6.2 Miltenyi Biotec Business Overview
- 8.6.3 Miltenyi Biotec IL-12 Antibody Revenue and Gross Margin (2021-2026)
- 8.6.4 Miltenyi Biotec IL-12 Antibody Product Portfolio
- 8.6.5 Miltenyi Biotec Recent Developments
- 8.7 NSJ Bioreagents
- 8.7.1 NSJ Bioreagents Company Information
- 8.7.2 NSJ Bioreagents Business Overview
- 8.7.3 NSJ Bioreagents IL-12 Antibody Revenue and Gross Margin (2021-2026)
- 8.7.4 NSJ Bioreagents IL-12 Antibody Product Portfolio
- 8.7.5 NSJ Bioreagents Recent Developments
- 8.8 ProSci
- 8.8.1 ProSci Company Information
- 8.8.2 ProSci Business Overview
- 8.8.3 ProSci IL-12 Antibody Revenue and Gross Margin (2021-2026)
- 8.8.4 ProSci IL-12 Antibody Product Portfolio
- 8.8.5 ProSci Recent Developments
- 8.9 Proteintech
- 8.9.1 Proteintech Company Information
- 8.9.2 Proteintech Business Overview
- 8.9.3 Proteintech IL-12 Antibody Revenue and Gross Margin (2021-2026)
- 8.9.4 Proteintech IL-12 Antibody Product Portfolio
- 8.9.5 Proteintech Recent Developments
- 8.10 Santa Cruz Biotechnology
- 8.10.1 Santa Cruz Biotechnology Company Information
- 8.10.2 Santa Cruz Biotechnology Business Overview
- 8.10.3 Santa Cruz Biotechnology IL-12 Antibody Revenue and Gross Margin (2021-2026)
- 8.10.4 Santa Cruz Biotechnology IL-12 Antibody Product Portfolio
- 8.10.5 Santa Cruz Biotechnology Recent Developments
- 8.11 United States Biological
- 8.11.1 United States Biological Company Information
- 8.11.2 United States Biological Business Overview
- 8.11.3 United States Biological IL-12 Antibody Revenue and Gross Margin (2021-2026)
- 8.11.4 United States Biological IL-12 Antibody Product Portfolio
- 8.11.5 United States Biological Recent Developments
- 8.12 Thermo Fisher Scientific
- 8.12.1 Thermo Fisher Scientific Company Information
- 8.12.2 Thermo Fisher Scientific Business Overview
- 8.12.3 Thermo Fisher Scientific IL-12 Antibody Revenue and Gross Margin (2021-2026)
- 8.12.4 Thermo Fisher Scientific IL-12 Antibody Product Portfolio
- 8.12.5 Thermo Fisher Scientific Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst